Neimeth Launches Co- Amoxiclav – Anti-Bioticneimethpharma
Neimeth International Pharmaceuticals Plc recently increased her Portfolio of diverse therapeutic entities with the introduction of Co- Amoxiclav, a potent antibiotic.
Co-Amoxiclav is a combination of Amoxicillin Trihydrate and Clavulanate Potassium.
Amoxicillin and Clavulanate are indicated for the short term treatment of common bacterial infections such as, Upper Respiratory Tract Infections (including ENT) e.g. tonsillitis, sinusitis, otitis media. Lower Respiratory Tract e.g. Acute and chronic bronchitis, lobar and broncho – pneumonia, Genito – urinary Tract infections e.g. Cystitis, urethritis, pyelonephritis, female genital infections. Skin and Soft tissue infection.
Launching the product, the product Manager, Dr Chidi Ibegbu presented the product as highly cost-effective compared to competing brands. Speaking further, he said that the product also has the MAS (Mobile Authentication System) that gives the product credibility and allow consumers to determine the authenticity of the product before buying. Co- Amoxiclav also comes in attractive consumer –friendly packs and is packaged as film coated Tablets and Paediatric Suspension for Oral Administration.
The product is scheduled to be launched to key Distributors and Prescribers in the 6 Geo-political areas Pan Nigeria and has already taken place in key drug distribution centres in Lagos, Onitsha and Aba. It will spread to other centres in February, 2015. The second phase of the launch also scheduled for February 2015 will cover Teaching Hospitals, Private Hospitals Professional bodies (Nigerian Medical Association, Pharmaceutical Society of Nigeria, Association of Community Pharmacists, National Association of Industrial Pharmacists) to mention a few.
Beyond Co-Amoxiclav, Neimeth has heavy pipeline of products currently at different levels of R&D in diverse therapeutic entities that are ready for launch .